Stories about Qutenza

29.09.2021 – 10:02
Grünenthal Group
First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist
Aachen (ots) - Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its peripherally restricted Nociceptin/Orphanin FQ peptide receptor (NOP) agonist. The compound is being developed to provide a non-opioid therapy option that ...
more
30.03.2021 – 13:37
Grünenthal Group
Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain
Aachen, Germany, & Morristown, N.J. (ots) - - Post-surgical neuropathic pain (PSNP) is a debilitating complication of surgery that affects approximately 13 percent of all patients who undergo surgery, which represents 3.3 million patients per year in the US[1] - This Phase III study is Grünenthal’s next step in ...
more